Voxel-based correlation of $^{18}$F-THK5351 accumulation and gray matter volume in the brain of cognitively normal older adults

Yoko Shigemoto$^{1,2,*}$, Daichi Sone$^{1,3}$, Miho Ota$^{4}$, Norihide Maikusa$^{1}$, Masayo Ogawa$^{1}$, Kyoji Okita$^{1,5}$, Harumasa Takano$^{1}$, Koichi Kato$^{1}$, Yukio Kimura$^{2}$, Emiko Morimoto$^{2}$, Fumio Suzuki$^{2}$, Hiroyuki Fujii$^{2}$, Noriko Sato$^{2}$ and Hiroshi Matsuda$^{1}$

Abstract

Backgrounds: Although neurofibrillary tangles (NFTs) mainly accumulate in the medial temporal lobe with human aging, only a few imaging studies have investigated correlations between NFT accumulation and gray matter (GM) volume in cognitively normal older adults. Here, we investigated the correlations between $^{18}$F-THK5351 accumulation and GM volume at the voxel level.

Material and methods: We recruited 47 amyloid-negative, cognitively normal, older adults (65.0 ± 7.9 years, 26 women), who underwent structural magnetic resonance imaging, $^{11}$C-Pittsburgh compound-B and $^{18}$F-THK5351 PET scans, and neuropsychological assessment. The magnetic resonance and $^{18}$F-THK5351 PET images were spatially normalized using Statistical Parametric Mapping 12. Voxel-wise correlations between $^{18}$F-THK5351 accumulation and GM volume were evaluated using the Biological Parametric Mapping toolbox.

Results: A significant negative correlation ($p < 0.001$) between $^{18}$F-THK5351 accumulation and GM volume was detected in the bilateral medial temporal lobes.

Conclusions: Voxel-wise correlation analysis revealed a significant negative correlation between $^{18}$F-THK5351 accumulation and GM volume in the medial temporal lobe in individuals without amyloid-β deposits. These results may contribute to a better understanding of the pathophysiology of primary age-related tauopathy in human aging.

Keywords: Cognitively normal older adult, Medial temporal lobe, $^{18}$F-THK5351 PET, Gray matter volume, Primary age-related tauopathy

Introduction

Neuropathological studies have revealed that neurofibrillary tangles (NFTs) mainly accumulate in the medial temporal lobe (MTL) with human aging. Although neurodegeneration is also a feature of aging, in addition to tau pathology, only a few imaging studies have specifically investigated correlations between tau accumulation and brain volume [1, 2]. Although $^{18}$F-THK5351 was originally developed as a tau-specific tracer, recent studies have clarified the off-target binding to monoamine oxidase B (MAO-B) [3]. Because $^{18}$F-THK5351 accumulation reflects the combination of astrogliosis, in addition to tau pathology, it is now considered the promising biomarker for detecting neuroinflammation [4]. Previously, using region of interest (ROI) analysis, we did not detect significant negative correlations between $^{18}$F-THK5351 accumulation and gray matter (GM) volume [5]. In this study, we aimed to re-examine the correlations between $^{18}$F-THK5351 accumulation and GM volume at the voxel level.
Materials and methods
Participants
We recruited 47 cognitively normal older adults from the Brain Mapping by Integrated Neurotechnologies for Disease Studies (Brain/MINDS) project (grant number 18dm0207017h0005), who underwent structural magnetic resonance imaging and $^{11}$C-Pittsburgh compound-B (PiB) and $^{18}$F-THK5351 PET scans. All participants underwent cognitive testing that included the Mini-Mental State Examination (MMSE), global Clinical Dementia Rating Scale (CDR), and Wechsler Memory Scale-Revised Logical Memory Scale (WMSR LM-II). The inclusion criteria were the following: visually negative PiB PET results, a global cognitive testing that included the Mini-Mental State Examination, and performance within education-adjusted norms for WMSR LM-II, absence of neurological or psychiatric disorders, and no medications that affect cognition.

Data acquisition
All participants underwent 3D T1-weighted scans with a 3-T magnetic resonance imaging system (Verio; Siemens, Erlangen, Germany). PET scans were acquired using a Siemens/BrainPointTruePoint16 Scanner (3D acquisition mode; 81 image planes; 16.2-cm axial field of view; 4.2-mm transaxial resolution; 4.7-mm axial resolution; 2-mm slice interval). For $^{11}$C-PiB imaging, participants were injected with $555 \pm 185$ MBq of PiB prior to imaging and imaging was performed for a 20-min PET acquisition, $50 \pm 5$ min post-injection. For $^{18}$F-THK5351 imaging, participants were injected with $185 \pm 37$ MBq of THK5351 prior to imaging and imaging was performed for a 20-min PET acquisition, $40 \pm 5$ min post-injection. PET/CT data were reconstructed using an iterative 3D ordered subset expectation maximization reconstruction algorithm.

Data preprocessing
The partial volume corrected $^{18}$F-THK5351 PET images using PETPVE12 toolbox [6] were normalized using SPM12 (Statistical Parametric Mapping 12; Wellcome Department of Cognitive Neurology, London, England). Each participant’s $^{18}$F-THK5351 PET image was coregistered to its T1-weighted image and normalized with Diffeomorphic Anatomical Registration Through Exponentiated Lie Algebra. A transformation matrix was applied to each $^{18}$F-THK5351 PET image, which had been coregistered to the T1-weighted images. After spatial normalization, standardized uptake value ratios (SUVRs) for $^{18}$F-THK5351 PET images were calculated using the individual’s positive mean uptake value of cerebellar GM as the reference region. Finally, each PET image was smoothed by an 8-mm full width at half maximum (FWHM) Gaussian kernel. The GM images segmented using SPM12 were also normalized and smoothed using an 8-mm FWHM Gaussian kernel.

Statistical analyses
The Biological Parametric Mapping (BPM) toolbox allows voxel-level comparisons across imaging modalities based on the general linear model to perform regressions [7]. Using the BPM toolbox, we evaluated the direct correlations between $^{18}$F-THK5351 accumulation and GM volume at the voxel level. Results were considered significant at $p < 0.001$ with an extent threshold of 30 voxels (uncorrected for multiple comparisons).

Results
The participants’ demographics are shown in Table 1. Mean age ± standard deviation was $65.0 \pm 7.9$ years and mean cognitive scores were $29.3 \pm 1.1$ for MMSE and $13.4 \pm 2.9$ for WMSR LM-II.

| Participants’ demographics | Cognitively normal older adults |
|-----------------------------|--------------------------------|
| No. (% women)               | 47 (26)                        |
| Age, year                   | $65.0 \pm 7.9$ [50–86]         |
| Education, year             | $14.3 \pm 2.4$ [9–22]          |
| MMSE                        | $29.3 \pm 1.1$ [26–30]         |
| WMSR LM-II                  | $13.4 \pm 2.9$ [8–19]          |

Values are mean ± standard deviation [range]. MMSE Mini-Mental State Examination, WMSR LM-II Wechsler Memory Scale-Revised Logical Memory II.
Fig. 1 Mean SUVR images of $^{18}$F-THK5351 in cognitively normal older adults. Localized $^{18}$F-THK5351 accumulation was mainly evident in the basal ganglia, thalamus, and medial temporal lobe, which slightly extended to the inferior temporal lobe, insula, posterior cingulate gyrus/precuneus, and basal frontal lobe. SUVR, standardized uptake value ratio.

Fig. 2 Voxel-wise correlations between $^{18}$F-THK5351 accumulation and gray matter volume in normal older adults. Significant negative correlations between $^{18}$F-THK5351 accumulation and gray matter volume were detected in the bilateral medial temporal lobes (voxel threshold of $p < 0.001$ with a 30-voxel extent threshold). A anterior, P posterior, R right, L left.
posterior cingulate cortex/precuneus, and basal frontal lobe. Our finding corresponded to Braak stage III–IV, which is not consistent with previous neuropathological and tau PET studies that tau pathology was usually localized in the MTL in the cognitively healthy participants [8, 9]. However, a recent large cohort study [10] showed elevated 18F-THK5351 tau tracer retentions in Braak stage III–IV areas with normal amyloid status and raised the possibility of primary age-related tauopathy (PART) [11]. Our results also support their results and might reflect PART. PART is defined as NFT pathology mostly restricted to the MTL, basal forebrain, brainstem, and olfactory areas in the absence of β-amyloid in the aged brain. Cognitive function is usually normal to mildly impaired in PART, and severe cognitive decline is rarely seen. Although PART is suggested to be an age-related phenomenon distinct from early Alzheimer’s disease, its pathophysiology is still unclear [1]. Thus, further studies with tau PET are needed to better understand the pathogenesis of PART.

The BPM analysis demonstrated a significant voxel-wise negative correlation between 18F-THK5351 accumulation and GM volume in the MTL, which was not detected in the previous ROI-based analysis [5]. Although ROI analysis is a common approach, it may not be able to accurately assess localized accumulation due to dilution effects. Because the BPM toolbox enables a direct comparison across imaging modalities at the voxel level, this voxel-based analysis may be more reliable than traditional ROI-based analyses. Our findings are consistent with neuropathological studies of PART patients showing that a higher Braak NFT stage is associated with hippocampal head atrophy [1]. Similar findings have been reported in recent 18F-AV1451 tau PET studies, namely, that higher MTL tau is associated with MTL atrophy [2]. Although they managed to obtain these results using a predefined FreeSurfer ROI approach, it is possible that nonspecific 18F-AV1451 accumulation in the choroid plexus adjacent to the MTL may not have been eliminated.

This study has several limitations. First, the number of participants was relatively small. Second, the study lacked pathologic confirmation of tau pathology. Third, the high affinity of 18F-THK5351 to MAO-B [3, 4] may contribute to the relatively higher Braak stage of our findings compared to PART type pathology which is usually III or lower [11]. MAO-B concentration increases during ongoing astrogliosis, which is considered as neuroinflammation changes that occur in response to brain injury and neurodegenerative disease [12]. Previous PET study in healthy subjects reported global MAO-B increases in the whole brain even with human aging [13], and the astrocytes seem to contribute to low-grade inflammation in the aged brain [14]. Because 18F-THK5351 uptake reflects the combination of astrogliosis and tau pathology, the degree and extent of tracer retention could be higher than that of only tau pathology. Recently, it is reported that aggregation of misfolded proteins including TDP-43 and α-synuclein in addition to Aβ and NFTs observed in PART are common even in cognitively healthy elderly brain [15]. Since the mixed pathologies are frequently observed in the aged brain, they could evoke neuroinflammation and increase astrogliosis, resulting in accumulation of 18F-THK5351. The early phase of age-related TDP-43 accumulation, known as “limbic-predominant age-related TDP-43 encephalopathy (LATE),” which tends to extend to limbic areas including the amygdala, could be part of the reasons [16]. In addition, the stereological cell counting studies showed declining of neocortical neuronal populations but no changes of the total astrocyte numbers in the aged human brains [17]. Therefore, the numbers of astrocytes would tend to concentrate in the atrophied MTL regions, suggesting the contribution of MAO-B in addition to tau pathology.

In summary, we found significant voxel-wise negative correlations between 18F-THK5351 accumulation and GM volume in the MTL. These results may reflect the concept of PART and contribute to a better understanding of the neurobiology of aging. Further studies are needed to confirm whether our findings reflect PART pathology or not by taking an oral dose of MAO-B inhibitor selegiline [3] or using second-generation tau-specific tracers with much less off-target binding.

Abbreviations

BPM: Biological Parametric Mapping; CDR: Clinical Dementia Rating; FWHM: Full width at half maximum; GM: Gray matter; MAO-B: Monoamine oxidase B; MMSE: Mini-Mental State Examination; MTL: Medial temporal lobe; NFT: Neurofibrillary tangle; PART: Primary age-related tauopathy; PiB: Pittsburgh compound-B; ROI: Region of interest; SPM: Statistical Parametric Mapping; SUVR: Standardized uptake value ratio; WMSR LM-II: Wechsler Memory Scale-Revised Logical Memory II

Acknowledgements

We would like to thank the technical staff of the Radiological Department at the National Center of Neurology and Psychiatry.

Authors’ contributions

YS and HM designed the study, performed the analysis, and wrote the manuscript. KO, HT, MO, and KK collected the data and carried out the experiments. MO and NM gave technical support. DS, YK, EM, FS, and HF participated in the data investigation. NS revised the manuscript. All authors read and approved the final manuscript.

Funding

This study was funded by the Brain Mapping by Integrated Neurotechnologies for Disease Studies (Brain/MINDS) project (grant no. 18dm0207017h0005) from the Japan Agency for Medical Research and Development (AMED).

Availability of data and materials

The datasets used and analyzed during the current study are available from the corresponding author on reasonable request.
Ethics approval and consent to participate
All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards. All participants gave written informed consent to participate in the study, which was approved by the institutional ethics committee at the National Center of Neurology and Psychiatry (A2014-146).

Consent for publication
Not applicable

Competing interests
The authors declare that they have no competing interests.

Author details
1 Integrative Brain Imaging Center, National Center of Neurology and Psychiatry, 4-1-1, Ogawa-Higashi, Kodaira, Tokyo 187-8551, Japan. 2 Department of Radiology, National Center of Neurology and Psychiatry, 4-1-1, Ogawa-Higashi, Kodaira, Tokyo 187-8551, Japan. 3 Department of Clinical and Experimental Epilepsy, UCL Institute of Neurology, University College London, Gower Street, London WC1E 6BT, UK. 4 Division of Clinical Medicine, Department of Neuropsychiatry, Faculty of Medicine, University of Tsukuba, 1-1-1, Tennodai, Tsukuba, Ibaraki 305-8576, Japan. 5 Department of Drug Dependence Research, National Institute of Mental Health, National Center of Neurology and Psychiatry, 4-1-1, Ogawa-Higashi, Kodaira, Tokyo 187-8551, Japan.

Received: 8 June 2019 Accepted: 12 August 2019
Published online: 23 August 2019

References
1. Josephs KA, Munsay ME, Tosakulwong N, Whitwell JL, Knopman DS, Machulda MM, et al. Tau aggregation influences cognition and hippocampalatrophy in the absence of beta-amyloid: a clinic-imaging -pathological study of primary age-related tauopathy (PART). Acta Neuropathol. 2017;133:705–15. https://doi.org/10.1007/s00401-017-1681-2.
2. Maass A, Lockhart SN, Harrison TM, Bell RK, Mellinger T, Swinnerton K, et al. Entorhinal tau pathology, episodic memory decline, and neurodegeneration in aging. J Neurolsci. 2018;38:530–43. https://doi.org/10.1523/JNEUROSCI.2028-17.2017.
3. Ng KP, Pascoal TA, Mathotaarachchi S, Therriault J, Kang MS, Shin M, et al. Monoamine oxidase B inhibitor, selegiline, reduces 18F-THK5351 uptake in the human brain. Alzheimer’s Res Ther. 2017;9:25. https://doi.org/10.1186/s13195-017-0253-y.
4. Okamura N, Harada R, Ishiki A, Kikuchi A, Nakamura T, Kudo Y. The development and validation of tau PET tracers: current status and future directions. Clin Transl Imaging. 2018;6:305–16. https://doi.org/10.1007/s40336-018-0290-y.
5. Shigemoto Y, Sone D, Imabayashi E, Maikusa N, Okamura N, Furuto M, et al. Dissociation of tau deposits and brain atrophy in early Alzheimer’s disease: a combined positron emission tomography/magnetic resonance imaging study. Front Aging Neurosci. 2018;10:223. https://doi.org/10.3389/fnagi.2018.00223.
6. Gonzalez-Escamilla G, Lange C, Teipel S, Buchert R, Grothe MJ, Alzheimer’s Disease Neuroimaging Initiative. PETPVE12: an SPM toolbox for partial volume effects correction in brain PET - application to amyloid imaging with AV45-PET. Neuroimage. 2017;147:669–77. https://doi.org/10.1016/j.neuroimage.2016.12.077.
7. Casanova R, Srirangan R, Baer A, Laurienti PJ, Burdette JH, Hayashaka S, et al. Biological parametric mapping: a statistical toolbox for multimodality brain image analysis. Neuroimage. 2007;34:137–43.
8. Braak H, Braak E. Neuropathological staging of Alzheimer-related changes. Acta Neuropathol. 1991;82:239–59.
9. Braak H, Braak E. Frequency of stages of Alzheimer-related lesions in different age categories. Neurobiol Aging. 1997;18:351–7.
10. Lowe VJ, Wiste HJ, Senjem ML, Weigand SD, Thernau TM, Boeve BF, et al. Widespread brain tau and its association with ageing, Braak stage and Alzheimer’s dementia. Brain. 2018;141:271–87. https://doi.org/10.1093/brain/awx320.
11. Crain JF, Trojanowski JQ, Schneider JA, Abisambra JF, Abner EL, Alafuzoff I, et al. Primary age-related tauopathy (PART): a common pathology associated with human aging. Acta Neuropathol. 2014;128:755–66. https://doi.org/10.1007/s00401-014-1349-0.
12. Sofroniew MV. Molecular dissection of reactive astrogliosis and glial scar formation. Trends Neurosci. 2009;32:638–47. https://doi.org/10.1016/j.tins.2009.08.002.
13. Fowler JS, Volkow ND, Wang GJ, Logan J, Pappas N, Shea C, et al. Age-related increases in brain monoamine oxidase B in living healthy human subjects. Neurobiol Aging. 1997;18:431–5.
14. Palmer AL, Ousman SS. Astrocytes and aging. Front Aging Neurosci. 2018;10:337. https://doi.org/10.3389/fnagi.2018.00337.
15. Elbedir L, Libard S, Leino M, Popova SN, Alafuzoff I. Altered proteins in the aging brain. J Neuropathol Exp Neurol. 2016;75:316–25. https://doi.org/10.1093/jnenl/nlw002.
16. Nelson PT, Dickson DW, Trojanowski JQ, Jack CR, Boyle PA, Arfanakis K, et al. Limbic-predominant age-related TDP-43 encephalopathy (LATE): consensus working group report. Brain. 2019;142:1503–27. https://doi.org/10.1093/brain/awz099.
17. Wallae S, Pakkenberg B, Fabricius K. Stereological estimation of total cell numbers in the human cerebral and cerebellar cortex. Front Hum Neurosci. 2014;8:508. https://doi.org/10.3389/fnhum.2014.00508.

Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.